complete and sustained objective response per recist to irvalec (pm02734) in undifferentiated large cell esophageal adenocarcinoma: a case report and a review of the literature

Clicks: 181
ID: 171261
2012
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Undifferentiated large cell carcinoma is a rare entity in esophageal cancer and very few data are available in the literature on this uncommon histological subtype. We report a case of a 58-year-old Caucasian male previously treated with cisplatin/5-fluorouracil, docetaxel and carboplatin/plitidepsin who received treatment with a novel antitumor agent, Irvalec (PM02734), as fourth line. The patient received treatment from July 2006 to July 2009, a total of 49 cycles, at a dose of 2.4 mg/m2 as a 24-hour infusion every 3 weeks. He did not present severe complications or unplanned or cumulative toxicities. Complete and durable response according to RECIST was reported. He was alive at the last follow-up on March 2012.
Reference Key
salazar2012casecomplete Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Ramón Salazar;Carmen Cuadra;Marta Gil-Martín;Andrea Vandermeeren;Vicente Alfaro;Cinthya Coronado
Journal multi-span large bridges - proceedings of the international conference on multi-span large bridges, 2015
Year 2012
DOI
10.1159/000341104
URL
http://www.karger.com/Article/FullText/341104
Keywords
esophageal cancer Oncology including cancer and carcinogens tumors chemotherapyneoplasms irvalec

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.